TY - JOUR
T1 - Recommendations for the management of herpes zoster
AU - Dworkin, Robert H.
AU - Johnson, Robert W.
AU - Breuer, Judith
AU - Gnann, John W.
AU - Levin, Myron J.
AU - Backonja, Miroslav
AU - Betts, Robert F.
AU - Gershon, Anne A.
AU - Haanpää, Maija L.
AU - McKendrick, Michael W.
AU - Nurmikko, Turo J.
AU - Oaklander, Anne Louise
AU - Oxman, Michael N.
AU - Pavan-Langston, Deborah
AU - Petersen, Karin L.
AU - Rowbotham, Michael C.
AU - Schmader, Kenneth E.
AU - Stacey, Brett R.
AU - Tyring, Stephen K.
AU - Van Wijck, Albert J.M.
AU - Wallace, Mark S.
AU - Wassilew, Sawko W.
AU - Whitley, Richard J.
PY - 2007/1/1
Y1 - 2007/1/1
N2 - The objective of this article is to provide evidence-based recommendations for the management of patients with herpes zoster (HZ) that take into account clinical efficacy, adverse effects, impact on quality of life, and costs of treatment. Systematic literature reviews, published randomized clinical trials, existing guidelines, and the authors' clinical and research experience relevant to the management of patients with HZ were reviewed at a consensus meeting. The results of controlled trials and the clinical experience of the authors support the use of acyclovir, brivudin (where available), famciclovir, and valacyclovir as first-line antiviral therapy for the treatment of patients with HZ. Specific recommendations for the use of these medications are provided. In addition, suggestions are made for treatments that, when used in combination with antiviral therapy, may further reduce pain and other complications of HZ.
AB - The objective of this article is to provide evidence-based recommendations for the management of patients with herpes zoster (HZ) that take into account clinical efficacy, adverse effects, impact on quality of life, and costs of treatment. Systematic literature reviews, published randomized clinical trials, existing guidelines, and the authors' clinical and research experience relevant to the management of patients with HZ were reviewed at a consensus meeting. The results of controlled trials and the clinical experience of the authors support the use of acyclovir, brivudin (where available), famciclovir, and valacyclovir as first-line antiviral therapy for the treatment of patients with HZ. Specific recommendations for the use of these medications are provided. In addition, suggestions are made for treatments that, when used in combination with antiviral therapy, may further reduce pain and other complications of HZ.
UR - http://www.scopus.com/inward/record.url?scp=33845634835&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33845634835&partnerID=8YFLogxK
U2 - 10.1086/510206
DO - 10.1086/510206
M3 - Review article
C2 - 17143845
AN - SCOPUS:33845634835
VL - 44
SP - S1-S26
JO - Clinical Infectious Diseases
JF - Clinical Infectious Diseases
SN - 1058-4838
IS - SUPPL. 1
ER -